口服泊沙康唑混悬液在免疫受损儿童中的目标浓度达标评估
本回顾性研究纳入70例<13岁免疫受损儿童,接受泊沙康唑混悬液5 mg/kg每8小时预防性治疗至少7天。平均血浆浓度为783.4 ng/mL,仅47.9%患者达到≥700 ng/mL的目标浓度;合并使用质子泵抑制剂、H2受体拮抗剂或甲氧氯普胺、黏膜炎或肠内喂养者浓度显著更低(542.3 vs 1069.8 ng/mL,P<0.001)。突破性侵袭性真菌感染率为4.3%(3/70)。
要点
- 初始5 mg/kg每8小时泊沙康唑混悬液仅47.9%免疫受损儿童达到≥700 ng/mL目标浓度。
- 合并质子泵抑制剂、H2受体拮抗剂、甲氧氯普胺、黏膜炎或肠内喂养者泊沙康唑浓度显著降低。
- 突破性侵袭性真菌感染率为4.3%(3/70),需研究新型泊沙康唑制剂。
核心结论
- 5 mg/kg每8小时泊沙康唑混悬液仅使47.9%的免疫受损儿童达到≥700 ng/mL目标浓度。
- 需进一步研究新型泊沙康唑制剂以改善儿童目标浓度达标率。
研究设计与样本
- 回顾性研究,纳入70例<13岁免疫受损儿童,接受泊沙康唑混悬液5 mg/kg每8小时预防性治疗≥7天,并测定泊沙康唑浓度。
主要发现
- 中位年龄5岁(范围3个月至12岁),平均泊沙康唑血浆浓度783.4 ng/mL(IQR 428.3-980 ng/mL)。
- 达到泊沙康唑血浆浓度≥700 ng/mL的患者比例为47.9%。
- 合并使用质子泵抑制剂、H2受体拮抗剂或甲氧氯普胺、黏膜炎或肠内喂养者泊沙康唑浓度较低(542.3 vs 1069.8 ng/mL;P<0.001)。
- 突破性侵袭性真菌感染率为4.3%(3/70)。
关键数值与推荐
- 目标泊沙康唑血浆浓度≥700 ng/mL。
- 初始预防剂量为泊沙康唑混悬液5 mg/kg每8小时。
临床怎么用
- 对<13岁免疫受损儿童使用泊沙康唑混悬液预防时,需注意目标浓度达标率仅47.9%。
- 对合并使用质子泵抑制剂、H2受体拮抗剂、甲氧氯普胺、黏膜炎或肠内喂养的患儿应警惕泊沙康唑浓度降低。
局限性
- 回顾性研究设计。
- 样本量70例,单中心数据。
- 仅评估泊沙康唑混悬液,未涉及其他剂型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posaconazole is a broad-spectrum antifungal that is not licensed for use in children <13 years of age. Despite this and by necessity, it is used extensively in paediatric hospitals for prophylaxis of invasive fungal disease. OBJECTIVES: To determine whether initial prophylactic dosing recommendations attain a posaconazole plasma concentration of ≥700 ng/mL in immunocompromised children <13 years of age. PATIENTS AND METHODS: We performed a retrospective study of immunocompromised children <13 years of age receiving posaconazole suspension prophylaxis at a starting dose of 5 mg/kg every 8 h for ≥7 days and who had a posaconazole concentration measured after ≥7 days. Posaconazole plasma concentrations and rate of breakthrough infection were recorded. RESULTS: A total of 70 patients were included with a median age of 5 years (range 3 months to 12 years). The mean posaconazole plasma concentration was 783.4 ng/mL (IQR 428.3-980 ng/mL) and the percentage of patients with a posaconazole plasma concentration ≥700ng/mL was 47.9%. Patients who were on a proton pump inhibitor, a histamine H2 antagonist or metoclopramide, had mucositis or were enterally fed had a lower posaconazole plasma concentration compared with patients without these co-administered drugs/mucositis/enteral feeding (542.3 versus 1069.8 ng/mL; P<0.001). The breakthrough invasive fungal infection rate was 4.3% (3/70). CONCLUSIONS: The studied 5 mg/kg posaconazole suspension every 8 h resulted in target concentrations in only 47.9% of patients and further studies looking at newer posaconazole formulations are needed.
引用
- Lai T, Alffenaar JW, Kesson A, et al. Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. J Antimicrob Chemother. 2020. PMID: 31855264. doi:10.1093/jac/dkz481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。